Loading
Prostatic acid phosphatase is an enzyme made almost only by the prostate; the cell vaccine sipuleucel-T trains a patient's immune cells against it.
Prostatic acid phosphatase (PAP, gene ACP3) is secreted by prostate epithelium and was the prostate cancer blood marker before PSA. Because it is nearly prostate-specific, it serves as the antigen for sipuleucel-T: the patient's antigen-presenting cells are loaded with a PAP-GM-CSF fusion protein and re-infused to raise an anti-PAP immune response in metastatic castration-resistant prostate cancer.
In plain words · Prostatic acid phosphatase is an enzyme made almost only by the prostate; the cell vaccine sipuleucel-T trains a patient's immune cells against it.
Prostatic acid phosphatase is an enzyme made almost only by the prostate; the cell vaccine sipuleucel-T trains a patient's immune cells against it.
A prostate-restricted phosphatase found in secreted and transmembrane forms; expression persists in most prostate cancers.
No product in this corpus aims at Prostatic acid phosphatase (ACP3, PAP) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Lineage antigen shared with normal granulocytes: HPA blood lineage lineage enhanced at or above 25 nTPM, and surface-antigen class aim at it, so normal cells of the lineage are hit too. HPA ACP3: RNA tissue enriched (prostate 3,410 nTPM); blood lineage lineage enhanced (granulocytes 140 nTPM); high antibody staining in 1 normal tissue; highest cancer staining prostate cancer (11 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (prostate cancer). (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas ACP3 tissue; Human Protein Atlas ACP3 pathology; Open Targets ENSG00000014257 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Vihko et al, FEBS Lett, 1988, "Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase". Source.
A prostate-restricted phosphatase found in secreted and transmembrane forms; expression persists in most prostate cancers.
RNA: tissue enriched (prostate 3,410 nTPM), detected in many normal tissues. Blood: lineage enhanced (granulocytes 140 nTPM).
Medium: Kidney.
RNA cancer enriched: Prostate Adenocarcinoma 2,891 pTPM.
HPA ACP3 tissue · HPA ACP3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | nearly all% | Prostatic acid phosphatase expressed by prostate epithelium and most prostate cancers, the antigen sipuleucel-T targets | cancer.gov |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"Prostatic acid phosphatase" OR ABSTRACT:"Prostatic acid phosphatase" OR TITLE:"ACP3, PAP" OR ABSTRACT:"ACP3, PAP" OR TITLE:"ACP3" OR ABSTRACT:"ACP3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Prostatic acid phosphatase (ACP3, PAP), not a curated reading list.
Shares Sipuleucel-T, Prostate cancer.
Shares Sipuleucel-T, Prostate cancer.
Shares Sipuleucel-T, Prostate cancer.
Shares Sipuleucel-T, Dendritic cell vaccines, Prostate cancer.
Shares Sipuleucel-T, Dendritic cell vaccines, Prostate cancer.
Shares Sipuleucel-T, Prostate cancer.